Retatrutide: What the Trials Show and Why You Cannot Get It

Retatrutide is one injectable molecule that switches on three metabolic hormone receptors at once. Two of them, GLP-1 and GIP, are territory tirzepatide already covers. The third is the glucagon receptor, and that is the genuinely new part. The phase 2 obesity trial describes it as an agonist of the GIP, GLP-1 and glucagon receptors given once weekly by subcutaneous injection. Glucagon signaling nudges the liver to release stored fuel and lifts resting energy expenditure, so the molecule is working on the burn side of the equation as well as the appetite side.

That third receptor is also why the drug behaves differently in the tables. Adding glucagon activity means the trial designers had to watch heart rate, glucose control and liver measures more closely than they would with a pure incretin drug. The phase 2 program in type 2 diabetes was built around exactly that question, testing whether glucose could still improve while glucagon receptors were being stimulated. It could, which is what carried the molecule forward. None of this makes retatrutide better by default. It makes it different, and different needs its own evidence.

Everything below comes from published trials or from company statements about trials, and this page says which is which every time. Retatrutide has never been sold as a medicine anywhere in the world, so there is no label, no prescribing information and no approved dose.

If a website has offered to sell you some, skip ahead to the section on vials sold as research chemicals. Nothing here is medical advice, and whether any of it applies to you is a question for a prescriber.

As of September 2026 retatrutide is not approved by FDA for anything. There is no approved application, no package insert and no pharmacy that can legally fill a prescription for it. A clinician who wanted to prescribe it for you has nothing to prescribe from. FDA states plainly that retatrutide and cagrilintide cannot be used in compounding under federal law, because they are not components of FDA-approved drugs and have not been found effective for any condition. That closes the compounding pharmacy route as well as the retail one.

The program is late-stage. The phase 3 TRIUMPH trials in obesity have read out, a phase 3 diabetes trial has been published in a peer-reviewed journal, and Eli Lilly said in July 2026 that it plans to submit a Biologics License Application for retatrutide to FDA in the first quarter of 2027. A submission is not an approval, and FDA review takes months after that. Treat the September 2026 date on this page as load-bearing, because this particular fact has a shelf life.

Two lawful ways to receive the drug do exist right now, and both run through the sponsor rather than through a pharmacy. One is enrollment in an ongoing trial. The other is a narrow pre-approval expanded access protocol. Neither is something a telehealth visit can arrange for you, and neither involves paying a vendor. Both are described in the last section of this page, with the registry entries you can read for yourself.

Start with the paper the brief is built on. In the 48-week phase 2 obesity trial of 338 adults, average weight change was 8.7% at 1 mg, 17.1% in the pooled 4 mg groups, 22.8% in the pooled 8 mg groups and 24.2% at 12 mg, against 2.1% with placebo. Weight loss of 15% or more was reached by 83% of the 12 mg group compared with 2% on placebo. That trial had not flattened out by week 48, which is the observation that drove the whole phase 3 program.

The diabetes side has a published phase 3 result. TRANSCEND-T2D-1 randomized 537 adults with type 2 diabetes and reported HbA1c falling 1.94% at 12 mg against 0.81% with placebo over 40 weeks, with body weight down 15.3% against 2.6%. The earlier 281-adult phase 2 diabetes trial established the dose range that study used. These two, plus the obesity phase 2, are the retatrutide evidence that has been through peer review and editorial scrutiny.

Independent syntheses now place the molecule in context rather than in isolation. A 2026 systematic review of 38 randomized trials covering 25,816 adults reported placebo-subtracted weight change of 22.1% for retatrutide, 19.0% for tirzepatide, 14.8% for subcutaneous semaglutide, 12.4% for orforglipron and 5.8% for liraglutide. A network meta-analysis of 58 trials put retatrutide at 22.10% with a credible interval of 18.60% to 25.60%. Cross-trial comparisons like these are indirect, so read them as ordering rather than as head-to-head proof.

The largest retatrutide numbers in circulation come from company announcements, and that matters. Eli Lilly reported in May 2026 that TRIUMPH-1 found average weight change of 19.0% at 4 mg, 25.9% at 9 mg and 28.3% at 12 mg over 80 weeks against 2.2% with placebo, with 30.3% at 104 weeks in an extension. The trial is registered as NCT05929066. Those figures have not yet passed through a journal's review, so the full data tables and the fine print are not public in the way the phase 2 tables are. The rest of the program reported over 2026. TRIUMPH-2 enrolled 1,152 adults with type 2 diabetes and reported weight change of 12.7%, 19.1% and 20.8% by dose against 4.0% with placebo, and TRIUMPH-3 enrolled 1,949 adults with severe obesity and cardiovascular disease, reporting 21.6% and 22.6% against 3.2%. The whole TRIUMPH program was designed as a basket of trials running over 5,800 participants.

The honest summary is that retatrutide has produced the largest average weight changes yet reported for a pharmacological obesity treatment, and that most of those specific numbers are still sponsor-reported. Both halves of that sentence are true at the same time. If you see a site quoting the biggest figure in circulation without mentioning that it is an unpublished topline from a 104-week extension arm, that site is selling you something.

The comparison that matters is not retatrutide against nothing. It is retatrutide, which you cannot get, against three medicines you can. Zepbound, tirzepatide, is FDA-approved for long-term weight management and for moderate to severe obstructive sleep apnea in adults with obesity. Wegovy, semaglutide, carries an indication for reducing major adverse cardiovascular events in adults with established cardiovascular disease plus obesity or overweight. Foundayo, orforglipron, is a once-daily oral GLP-1 receptor agonist approved for weight management.

On average weight change the indirect evidence does favor retatrutide, and it also flags a cost. The network meta-analysis reported low certainty evidence of higher treatment discontinuation rates with danuglipron and retatrutide. A drug that produces a larger average and is harder to stay on can end up level with a gentler one once you account for the arms that stop. That trade-off cannot be settled from toplines, and it is exactly the sort of thing peer review and a full label are for.

There is also a timing argument that gets ignored. An approved medicine started this month has a year of effect behind it by the time retatrutide could plausibly reach a pharmacy shelf, if it reaches one at all. Waiting for a better drug is a real choice with a real cost, and it is a conversation worth having with a clinician rather than with a forum.

The gastrointestinal profile looks like the class. TRIUMPH-1 reported nausea in 42.4% against 14.8% on placebo, diarrhea in 32.0% against 13.5% and constipation in 26.1% against 10.9%. What is less familiar is dysesthesia, an abnormal burning or tingling skin sensation. It was reported in 12.5% of one retatrutide group against 0.9% on placebo in the same trial. That is not a signal the GLP-1 drugs are known for, and it is the kind of finding a full published dataset needs to explain.

Tolerability got worse as doses went up, and it varied a lot by trial population. Discontinuation for adverse events in TRIUMPH-1 ran 4.1% to 11.3% by dose against 4.9% on placebo, while the knee osteoarthritis trial reported 12.2% at 9 mg and 18.2% at 12 mg against 4.0%. In the published phase 3 diabetes trial, discontinuation for adverse events was 2% to 5% against none on placebo, and two deaths in a 4 mg group were judged unrelated to the study drug.

Cardiovascular and kidney safety is genuinely unknown so far. A 10,000-participant outcomes trial is running with primary completion scheduled for February 2029. Surrogate markers look reasonable. A meta-analysis reported systolic blood pressure down 6.79 mmHg and LDL cholesterol down 13.10 mg/dL. Surrogates are not outcomes, and the history of metabolic medicine is full of drugs whose markers looked reassuring right up until a hard endpoint trial reported. Until 2029 there is nothing to say on cardiovascular benefit or harm.

The doses in the literature only exist inside a protocol. The phase 2 obesity trial ran groups from 1 mg up to a 12 mg target over 48 weeks, with slow escalation schedules that differed between the 8 mg and 12 mg arms. Phase 3 settled on 4 mg, 9 mg and 12 mg weekly targets. Escalation was not a formality. It is how the adverse event rates above were kept to the levels reported, and every dose came pre-measured and pre-checked.

None of that survives contact with a vial bought online. Those arrive as lyophilized powder with no approved concentration, so working out a dose means mixing it yourself and measuring it in units on an insulin syringe, from instructions written by whoever sold it. FDA has warned specifically about dosing errors with unapproved GLP-1 products sold this way, including doses far above what any protocol used.

A tenfold arithmetic slip in a kitchen is not a rare event. It is the predictable one.

So take the numbers in this section as description. They are not a recipe. There is no approved retatrutide dose because there is no approved retatrutide. Anyone publishing a dosing protocol for it is publishing something no regulator has reviewed and no pharmacist has checked, and they are not the ones who end up in an emergency department at 3am explaining what was in the syringe. If a clinician does not know what you took, they are treating you blind.

Search retatrutide and the first thing that greets you is a shop. These sites sell vials labeled for research use only, or not for human consumption, alongside dosing charts and before-and-after photos. The labeling is decoration. FDA told one seller that despite research-use-only wording, evidence from the website established the products were intended as drugs for human use, and that they are unapproved new drugs with no application in effect. The disclaimer exists to shift liability onto you. It does nothing to make the product legal.

There is a harder fact underneath. Retatrutide has no finished-drug registration in the United States at all. The only entries in the federal drug directory are bulk ingredient filings by chemical suppliers, which is the signature of a raw powder rather than a medicine. FDA has warned companies illegally selling unapproved products containing semaglutide, tirzepatide, retatrutide, survodutide or mazdutide falsely labeled for research purposes, noting they have been sold direct to consumers with dosing instructions.

The consequences are documented. A 2026 case report describes an adult with type 1 diabetes who developed impending diabetic ketoacidosis with ketonemia peaking at 4.3 mmol/L after using retatrutide bought online, with the partner who shared the supply also becoming unwell. Nobody could confirm what was in the vial. That is the whole problem in one sentence: with an unapproved product there is no identity check, no purity check, no sterility check and nobody to call.

There is no honest price to give you for retatrutide, and the absence is the most useful cost fact on this page. The federal NADAC dataset, which records what US pharmacies actually pay to acquire drugs, returns no rows for retatrutide at all. Not a high price. Not a specialty price. Nothing, because there is no lawful product to buy. Any figure you see quoted for retatrutide is a gray-market vendor's asking price for an unapproved chemical, which is not a medicine price in any meaningful sense.

The approved comparators do have real numbers. Reading the same NADAC file at its 19 August 2026 effective date, Zepbound single-dose pens sit at roughly $525.70 to $526.11 per mL and the multi-dose KwikPen at roughly $200.70 to $282.51 per mL. Wegovy pens range from about $435.36 per mL at the 2.4 mg strength up to roughly $653 per mL at the starting strengths, and orforglipron tablets come in at about $20.66 to $20.81 each. All of these are brand-flagged, so no generic exists yet.

Treat those as acquisition cost rather than as what you would pay. They exclude pharmacy margin, dispensing fees, manufacturer savings programs and whatever your insurance does or does not cover, and coverage for weight management varies enormously between plans. They are useful as a floor and as a sanity check. If an online seller quotes you a fraction of these numbers for something described as equivalent, the gap is telling you what you are actually buying.

If you want retatrutide specifically, there are two lawful doors and both are narrow. The first is a clinical trial. Registry listings show which retatrutide studies are recruiting and where, and enrollment is free to you but comes with eligibility criteria, randomization and the real chance of being assigned placebo. The long-term cardiovascular and kidney outcomes trial is one of the large ongoing studies, and the registry is the place to check current status rather than any commercial site.

The second door is expanded access. A pre-approval expanded access protocol is listed as available for adults with a BMI of 35 or above who have at least two serious or life-threatening obesity-related complications that have not responded to the best approved therapy, and who cannot take part in a trial. That request is made by your treating physician to the sponsor. It is not something a telehealth service arranges, and nobody charges you for the drug.

For most situations neither door applies, and the useful conversation is a different one. Worth raising with a clinician: which approved medicine fits your history and your kidney, thyroid, pancreatic and gallbladder risk; whether your plan covers weight management at all and what documentation it wants; what a realistic escalation schedule looks like; and how you would handle the gastrointestinal weeks. The published evidence base for the approved options is now large enough to compare them properly, which is more than retatrutide can offer today.